ETA-receptor antagonists or allosteric modulators?

Trends in Pharmacological Sciences

Volumn 32, Issue 6, 2011, Pages 345-351

  De Mey, Jo G R ^a,b   Compeer, Matthijs G ^a   Lemkens, Pieter ^a   Meens, Merlijn J P M T ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; ALPHA [[1 BUTYL 5 [2 [(2 CARBOXYPHENYL)METHOXY] 4 METHOXYPHENYL] 1H PYRAZOL 4 YL]METHYLENE] 6 METHOXY 1,3 BENZODIOXOLE 5 PROPANOIC ACID; ATRASENTAN; BOSENTAN; CALCITONIN GENE RELATED PEPTIDE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR TYPE A1; ENDOTHELIN RECEPTOR TYPE A1 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; UNCLASSIFIED DRUG; ENDOTHELIN; ENDOTHELIN A RECEPTOR; VASODILATOR AGENT;

ALLOSTERISM; ARTERY RESISTANCE; BINDING AFFINITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; COMPETITIVE INHIBITION; COMPLEX FORMATION; COVALENT BOND; DRUG BINDING SITE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; MOLECULAR MODEL; MUSCLE CONTRACTILITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; RECEPTOR BINDING; VASODILATATION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; NEOPLASM; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN BINDING; RAT; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; ENDOTHELINS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PAIN; PROTEIN BINDING; RATS; RECEPTOR, ENDOTHELIN A; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATOR AGENTS;

EID: 79957690381     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.02.018     Document Type: Review

References (72)

1. De Mey, J.G. et al. (1982) Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery. J. Pharmacol. Exp. Ther. 222, 166-173
2. Yanagisawa, M. et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415 (Pubitemid 18090241)
3. Davenport, A.P. (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev. 54, 219-226
4. De Mey, J. et al. (2009) Endothelin-1, an endogenous irreversible agonist in search of an allosteric inhibitor. Mol. Cell Pharmacol. 1, 246
5. Masaki, T. (2004) Historical review: endothelin. Trends Pharmacol. Sci. 25, 219-224
6. Hynynen, M.M. and Khalil, R.A. (2006) The vascular endothelin system in hypertension - recent patents and discoveries. Recent Patents Cardiovasc. Drug Discov. 1, 95-108
7. Khodorova, A. et al. (2009) Endothelin receptors and pain. J. Pain 10, 4-28
8. Kirkby, N.S. et al. (2008) The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br. J. Pharmacol. 153, 1105-1119 (Pubitemid 351415492)
9. Rosano, L. et al. (2010) The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299, R395-404
10. Yanagisawa, H. et al. (1998) Role of endothelin-1/endothelin-A receptor-mediated signaling pathway in the aortic arch patterning in mice. J. Clin. Invest. 102, 22-33
11. B receptors in cardiovascular disease. Annu. Rev. Pharmacol. Toxicol. 47, 731-759
12. Fukuroda, T. et al. (1994) Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. 199, 1461-1465
13. 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br. J. Pharmacol. 144, 115-122
14. Lin, H.Y. et al. (1991) Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 88, 3185-3189
15. Lefkowitz, R.J. (2004) Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 25, 413-422
16. A-receptor complexes. PLoS ONE 5, e10917
17. Deupi, X. and Kobilka, B.K. (2010) Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 25, 293-303
18. Ivey, M.E. et al. (2008) Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 199, 237-247
19. Smrcka, A.V. et al. (2008) G protein betagamma subunits as targets for small molecule therapeutic development. Comb. Chem. High Throughput Screen 11, 382-395
20. Bremnes, T. et al. (2000) Regulation and intracellular trafficking pathways of the endothelin receptors. J. Biol. Chem. 275, 17596-17604
21. Freedman, N.J. et al. (1997) Phosphorylation and desensitization of human endothelin A and B receptors. Evidence for G protein-coupled receptor kinase specificity. J. Biol. Chem. 272, 17734-17743
22. Morris, G.E. et al. (2010) Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2. Cardiovasc. Res. 85, 424-433
23. Whalen, E.J. et al. (2007) Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell 129, 511-522 (Pubitemid 46660966)
24. Gregan, B. et al. (2004) Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J. Biol. Chem. 279, 27679-27687
25. Lattig, J. et al. (2009) Structural determinants for selective recognition of peptide ligands for endothelin receptor subtypes ETA and ETB. J. Pept. Sci. 15, 479-491
26. Sakamoto, A. et al. (1993) The ligand-receptor interactions of the endothelin systems are mediated by distinct 'message' and 'address' domains. J. Cardiovasc. Pharmacol. 22 (Suppl. 8), S113-116
27. Breu, V. et al. (1995) Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors. Eur. J. Biochem. 231, 266-270
28. Masaki, T. et al. (1999) Structural basis of the function of endothelin receptor. Mol. Cell Biochem. 190, 153-156
29. Orry, A.J. and Wallace, B.A. (2000) Modeling and docking the endothelin G-protein-coupled receptor. Biophys. J. 79, 3083-3094
30. Webb, M.L. et al. (1996) Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity. Biochemistry 35, 2548-2556
31. Hilal-Dandan, R. et al. (1997) The quasi-irreversible nature of endothelin binding and G protein-linked signaling in cardiac myocytes. J. Pharmacol. Exp. Ther. 281, 267-273
32. Leff, P. (1995) The two-state model of receptor activation. Trends Pharmacol. Sci. 16, 89-97
33. Hall, D.A. (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412-1423
34. Sakamoto, A. et al. (1993) Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists. J. Biol. Chem. 268, 8547-8553
35. Hoare, S.R. (2005) Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov. Today 10, 417-427
36. Hoare, S.R. (2007) Allosteric modulators of class B G-protein-coupled receptors. Curr. Neuropharmacol. 5, 168-179
37. Conner, A.C. et al. (2002) Interaction of calcitonin-gene-related peptide with its receptors. Biochem. Soc. Trans. 30, 451-455
38. Conner, A.C. et al. (2007) Ligand binding and activation of the CGRP receptor. Biochem. Soc. Trans. 35, 729-732
39. Christopoulos, A. and Kenakin, T. (2002) G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374
40. Kenakin, T. and Miller, L.J. (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304
41. Conn, P.J. et al. (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41-54
42. Keov, P. et al. (2011) Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60, 24-35
43. Valant, C. et al. (2009) Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Interv. 9, 125-135
44. Kenakin, T. (2004) Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 25, 186-192
45. Talbodec, A. et al. (2000) Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol. Pharmacol. 57, 797-804
46. Blandin, V. et al. (2000) Allosteric inhibition of endothelin ETA receptors by 3,5-dibromosalicylic acid. Mol. Pharmacol. 58, 1461-1469
47. Neubig, R.R. et al. (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 55, 597-606
48. Warner, T.D. et al. (1994) Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br. J. Pharmacol. 112, 207-213 (Pubitemid 24151728)
49. Ihara, M. et al. (1992) Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 50, 247-255
50. Clozel, M. et al. (1994) Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270, 228-235
51. Doherty, A.M. et al. (1993) Structure-activity relationships of C-terminal endothelin hexapeptide antagonists. J. Med. Chem. 36, 2585-2594
52. Palmer, M.J. (2009) Endothelin receptor antagonists: status and learning 20 years on. Prog. Med. Chem. 47, 203-237
53. A-receptor mediated contractions in isolated rat mesenteric arteries are modulated by co-activation of ETB receptors. Br. J. Pharmacol. 133, 927-935
54. Sabaa, N. et al. (2008) Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J. Clin. Invest. 118, 1924-1933
55. B receptors. J. Pharmacol. Exp. Ther. 280, 1102-1108
56. Bhowmick, N. et al. (1998) The endothelin subtype A receptor undergoes agonist- and antagonist-mediated internalization in the absence of signaling. Endocrinology 139, 3185-3192 (Pubitemid 28512348)
57. Chiou, W.J. et al. (2000) 'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects. J. Cardiovasc. Pharmacol. 36, S48-S52
58. Christopoulos, A. (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198-210
59. De Mey, J.G. and Vanhoutte, P.M. (1982) Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ. Res. 51, 439-447
60. De Mey, J.G. et al. (2008) Functional antagonism between endogenous neuropeptide Y and calcitonin gene-related peptide in mesenteric resistance arteries. J. Pharmacol. Exp. Ther. 324, 930-937
61. Meens, M.J. et al. (2009) Calcitonin gene-related peptide selectively relaxes contractile responses to endothelin-1 in rat mesenteric resistance arteries. J. Pharmacol. Exp. Ther. 331, 87-95
62. Boulanger, C. and Luscher, T.F. (1990) Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 85, 587-590
63. Nakashima, M. and Vanhoutte, P.M. (1993) Endothelin-1 and -3 cause endothelium-dependent hyperpolarization in the rat mesenteric artery. Am. J. Physiol. 265, H2137-2141
64. Wiley, K.E. and Davenport, A.P. (2001) Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br. J. Pharmacol. 133, 568-574
65. Wang, Y. and Wang, D.H. (2004) Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am. J. Physiol. Heart Circ. Physiol. 287, H1868-1874
66. Brain, S.D. and Grant, A.D. (2004) Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 84, 903-934
67. Bautista, D.M. et al. (2005) Pungent products from garlic activate the sensory ion channel TRPA1. Proc. Natl. Acad. Sci. U.S.A. 102, 12248-12252
68. Caterina, M.J. et al. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824 (Pubitemid 27462969)
69. Luttrell, L.M. and Gesty-Palmer, D. (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 62, 305-330
70. Rajagopal, S. et al. (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386
71. Copeland, R.A. et al. (2006) Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730-739
72. Packeu, A. et al. (2010) Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach. Br. J. Pharmacol. 161, 1311-1328